TNFRSF18 and melanoma: Combining immune checkpoint inhibitors with immune factor antagonists (CD40, CD137, CD134, CD357) has demonstrated some synergistic benefits in the treatment of advanced melanoma in clinical studies (Wei et al., 2013).